{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:03:49Z","timestamp":1794953029544,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005562","name":"North Carolina Biotechnology Center","doi-asserted-by":"publisher","award":["2019-FLG-3812"],"award-info":[{"award-number":["2019-FLG-3812"]}],"id":[{"id":"10.13039\/100005562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005562","name":"North Carolina Biotechnology Center","doi-asserted-by":"publisher","award":["2019-FLG-3812"],"award-info":[{"award-number":["2019-FLG-3812"]}],"id":[{"id":"10.13039\/100005562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002489"],"award-info":[{"award-number":["UL1TR002489"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002489"],"award-info":[{"award-number":["UL1TR002489"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R25-NS094093"],"award-info":[{"award-number":["R25-NS094093"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA196589"],"award-info":[{"award-number":["T32CA196589"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA229938"],"award-info":[{"award-number":["R21 CA229938"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA193140"],"award-info":[{"award-number":["R01 CA193140"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37-CA260223"],"award-info":[{"award-number":["R37-CA260223"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41587-022-01245-x","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T10:03:25Z","timestamp":1648202605000},"page":"1250-1258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":214,"title":["Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3425-6456","authenticated-orcid":false,"given":"Pritha","family":"Agarwalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edikan A.","family":"Ogunnaike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-8328","authenticated-orcid":false,"given":"Anton","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-2084","authenticated-orcid":false,"given":"Frances S.","family":"Ligler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-8526","authenticated-orcid":false,"given":"Gianpietro","family":"Dotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2963-3293","authenticated-orcid":false,"given":"Yevgeny","family":"Brudno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"1245_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"1245_CR2","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1245_CR3","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","volume":"24","author":"G Enblad","year":"2018","unstructured":"Enblad, G. et al. A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin. Cancer Res. 24, 6185\u20136194 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1245_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/PPO.0000000000000031","volume":"20","author":"CA Ramos","year":"2014","unstructured":"Ramos, C. A., Savoldo, B. & Dotti, G. CD19-CAR trials. Cancer J. 20, 112\u2013118 (2014).","journal-title":"Cancer J."},{"key":"1245_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","volume":"15","author":"V Prasad","year":"2018","unstructured":"Prasad, V. Tisagenlecleucel\u2014the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat. Rev. Clin. Oncol. 15, 11\u201312 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1245_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1358\/dot.2018.54.3.2776625","volume":"54","author":"P Sharma","year":"2018","unstructured":"Sharma, P., King, G. T., Shinde, S. S., Purev, E. & Jimeno, A. Axicabtagene ciloleucel for the treatment of relapsed\/refractory B-cell non-Hodgkin\u2019s lymphomas. Drugs Today 54, 187\u2013198 (2018).","journal-title":"Drugs Today"},{"key":"1245_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrd.2018.74","volume":"17","author":"J Tang","year":"2018","unstructured":"Tang, J., Hubbard-Lucey, V. M., Pearce, L., O\u2019Donnell-Tormey, J. & Shalabi, A. The global landscape of cancer cell therapy. Nat. Rev. Drug Discov. 17, 465\u2013466 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1245_CR8","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMp1807382","volume":"379","author":"PB Bach","year":"2018","unstructured":"Bach, P. B. National coverage analysis of CAR-T therapies\u2014policy, evidence, and payment. N. Engl. J. Med. 379, 1396\u20131398 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1245_CR9","unstructured":"Hernandez, I. Analysis determines true cost for CAR T-cell therapy. Healio https:\/\/www.healio.com\/news\/hematology-oncology\/20180426\/analysis-determines-true-cost-for-car-tcell-therapy (2018)."},{"key":"1245_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0685-x","volume":"18","author":"Y Leyfman","year":"2018","unstructured":"Leyfman, Y. Chimeric antigen receptors: unleashing a new age of anti-cancer therapy. Cancer Cell Int. 18, 182 (2018).","journal-title":"Cancer Cell Int."},{"key":"1245_CR11","first-page":"SP35","volume":"24","author":"M Caffrey","year":"2018","unstructured":"Caffrey, M. With approval of CAR T-cell therapy comes the next challenge: payer coverage. Am. J. Manag. Care 24, SP35\u2013SP36 (2018).","journal-title":"Am. J. Manag. Care"},{"key":"1245_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson, H. J., Rafiq, S. & Brentjens, R. J. Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13, 370\u2013383 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1245_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1245_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1245_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1245_CR16","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res. 6, 1100\u20131109 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1245_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1172\/JCI85631","volume":"126","author":"Y Xu","year":"2016","unstructured":"Xu, Y. & Dotti, G. Selection bias: maintaining less-differentiated T cells for adoptive immunotherapy. J. Clin, Invest. 126, 35\u201337 (2016).","journal-title":"J. Clin, Invest."},{"key":"1245_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc3322","volume":"12","author":"L Gattinoni","year":"2012","unstructured":"Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12, 671\u2013684 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1245_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","volume":"18","author":"U Mock","year":"2016","unstructured":"Mock, U. et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy 18, 1002\u20131011 (2016).","journal-title":"Cytotherapy"},{"key":"1245_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/hgtb.2016.120","volume":"27","author":"TL Lu","year":"2016","unstructured":"Lu, T. L. et al. A rapid cell expansion process for production of engineered autologous CAR-T cell therapies. Hum. Gene Ther. Methods 27, 209\u2013218 (2016).","journal-title":"Hum. Gene Ther. Methods"},{"key":"1245_CR21","doi-asserted-by":"crossref","unstructured":"Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185\u2013199 (2020).","DOI":"10.1038\/s41573-019-0051-2"},{"key":"1245_CR22","doi-asserted-by":"crossref","unstructured":"Kim, D. W. & Cho, J.-Y. Recent advances in allogeneic CAR-T cells. Biomolecules 10, 263 (2020).","DOI":"10.3390\/biom10020263"},{"key":"1245_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813\u2013820 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"1245_CR24","doi-asserted-by":"publisher","first-page":"e1671761","DOI":"10.1080\/2162402X.2019.1671761","volume":"8","author":"S Agarwal","year":"2019","unstructured":"Agarwal, S., Weidner, T., Thalheimer, F. B. & Buchholz, C. J. In vivo generated human CAR T cells eradicate tumor cells. Oncoimmunology 8, e1671761 (2019).","journal-title":"Oncoimmunology"},{"key":"1245_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41434-020-00193-y","volume":"28","author":"IJC Dautzenberg","year":"2021","unstructured":"Dautzenberg, I. J. C., Rabelink, M. J. W. E. & Hoeben, R. C. The stability of envelope-pseudotyped lentiviral vectors. Gene Ther. 28, 89\u2013104 (2021).","journal-title":"Gene Ther."},{"key":"1245_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03705-y","volume":"9","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum, D., Joshi, N., Tao, W., Karp, J. M. & Peer, D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 9, 1410 (2018).","journal-title":"Nat. Commun."},{"key":"1245_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.progpolymsci.2011.06.003","volume":"37","author":"KY Lee","year":"2012","unstructured":"Lee, K. Y. & Mooney, D. J. Alginate: properties and biomedical applications. Prog. Polym. Sci. 37, 106\u2013126 (2012).","journal-title":"Prog. Polym. Sci."},{"key":"1245_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/microarrays4020133","volume":"4","author":"T Andersen","year":"2015","unstructured":"Andersen, T., Auk-Emblem, P. & Dornish, M. 3D cell culture in alginate hydrogels. Microarrays (Basel) 4, 133\u2013161 (2015).","journal-title":"Microarrays (Basel)"},{"key":"1245_CR29","doi-asserted-by":"publisher","first-page":"035003","DOI":"10.1088\/1758-5082\/2\/3\/035003","volume":"2","author":"CM Hwang","year":"2010","unstructured":"Hwang, C. M. et al. Fabrication of three-dimensional porous cell-laden hydrogel for tissue engineering. Biofabrication 2, 035003 (2010).","journal-title":"Biofabrication"},{"key":"1245_CR30","doi-asserted-by":"crossref","unstructured":"Agarwalla, P. et al. Scaffold\u2010mediated static transduction of T cells for CAR\u2010T cell therapy. Adv. Healthc. Mater. 9, e2000275 (2020).","DOI":"10.1002\/adhm.202000275"},{"key":"1245_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep21154","volume":"6","author":"IN Savina","year":"2016","unstructured":"Savina, I. N., Ingavle, G. C., Cundy, A. B. & Mikhalovsky, S. V. A simple method for the production of large volume 3D macroporous hydrogels for advanced biotechnological, medical and environmental applications. Sci. Rep. 6, 21154 (2016).","journal-title":"Sci. Rep."},{"key":"1245_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0142-9612(96)00181-0","volume":"18","author":"L Shapiro","year":"1997","unstructured":"Shapiro, L. & Cohen, S. Novel alginate sponges for cell culture and transplantation. Biomaterials 18, 583\u2013590 (1997).","journal-title":"Biomaterials"},{"key":"1245_CR33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/cmdc.201402527","volume":"10","author":"Y Brudno","year":"2015","unstructured":"Brudno, Y. et al. In vivo targeting through click chemistry. ChemMedChem 10, 617\u2013620 (2015).","journal-title":"ChemMedChem"},{"key":"1245_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nbt.4047","volume":"36","author":"AS Cheung","year":"2018","unstructured":"Cheung, A. S., Zhang, D. K. Y., Koshy, S. T. & Mooney, D. J. Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat. Biotechnol. 36, 160\u2013169 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1245_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nbt.3104","volume":"33","author":"SB Stephan","year":"2015","unstructured":"Stephan, S. B. et al. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat. Biotechnol. 33, 97\u2013101 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1245_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.actbio.2020.05.033","volume":"112","author":"CT Moody","year":"2020","unstructured":"Moody, C. T., Palvai, S. & Brudno, Y. Click cross-linking improves retention and targeting of refillable alginate depots. Acta Biomater. 112, 112\u2013121 (2020).","journal-title":"Acta Biomater."},{"key":"1245_CR37","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822\u20131826 (2011).","journal-title":"J. Clin. Invest."},{"key":"1245_CR38","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1089\/hum.2017.237","volume":"29","author":"S Stock","year":"2018","unstructured":"Stock, S. et al. Influence of retronectin-mediated T-cell activation on expansion and phenotype of CD19-specific chimeric antigen receptor T cells. Hum. Gene Ther. 29, 1167\u20131182 (2018).","journal-title":"Hum. Gene Ther."},{"key":"1245_CR39","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.actbio.2008.11.019","volume":"5","author":"Y Hori","year":"2009","unstructured":"Hori, Y., Winans, A. M. & Irvine, D. J. Modular injectable matrices based on alginate solution\/microsphere mixtures that gel in situ and co-deliver immunomodulatory factors. Acta Biomater. 5, 969\u2013982 (2009).","journal-title":"Acta Biomater."},{"key":"1245_CR40","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","volume":"25","author":"I Diaconu","year":"2017","unstructured":"Diaconu, I. et al. Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. Mol. Ther. 25, 580\u2013592 (2017).","journal-title":"Mol. Ther."},{"key":"1245_CR41","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"1245_CR42","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos, C. A. et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J. Clin. Invest. 127, 3462\u20133471 (2017).","journal-title":"J. Clin. Invest."},{"key":"1245_CR43","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI86000","volume":"126","author":"CA Ramos","year":"2016","unstructured":"Ramos, C. A. et al. Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains. J. Clin. Invest. 126, 2588\u20132596 (2016).","journal-title":"J. Clin. Invest."},{"key":"1245_CR44","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/sj.mt.6300350","volume":"16","author":"HN Vu","year":"2008","unstructured":"Vu, H. N., Ramsey, J. D. & Pack, D. W. Engineering of a stable retroviral gene delivery vector by directed evolution. Mol. Ther 16, 308\u2013314 (2008).","journal-title":"Mol. Ther"},{"key":"1245_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","volume":"28","author":"RE Tay","year":"2021","unstructured":"Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms. Cancer Gene Ther. 28, 5\u201317 (2021).","journal-title":"Cancer Gene Ther."},{"key":"1245_CR46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.21037\/atm.2019.12.03","volume":"7","author":"H Wen","year":"2019","unstructured":"Wen, H. et al. Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice. Ann. Transl. Med. 7, 735 (2019).","journal-title":"Ann. Transl. Med."},{"key":"1245_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"1245_CR48","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/imcb.12254","volume":"97","author":"AD McLellan","year":"2019","unstructured":"McLellan, A. D. & Ali Hosseini Rad, S. M. Chimeric antigen receptor T cell persistence and memory cell formation. Immunol. Cell Biol. 97, 664\u2013674 (2019).","journal-title":"Immunol. Cell Biol."},{"key":"1245_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"1245_CR50","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"1245_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19672-2","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nat. Commun. 11, 5902 (2020).","journal-title":"Nat. Commun."},{"key":"1245_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1109\/MCSE.2016.49","volume":"18","author":"J Gostick","year":"2016","unstructured":"Gostick, J. et al. OpenPNM: a pore network modeling package. Comput. Sci. Eng. 18, 60\u201374 (2016).","journal-title":"Comput. Sci. Eng."},{"key":"1245_CR53","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","volume":"108","author":"J Vera","year":"2006","unstructured":"Vera, J. et al. T lymphocytes redirected against the \u03ba light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108, 3890\u20133897 (2006).","journal-title":"Blood"},{"key":"1245_CR54","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1172\/JCI85834","volume":"126","author":"Y Xu","year":"2016","unstructured":"Xu, Y. et al. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J. Clin. Invest. 126, 2678\u20132688 (2016).","journal-title":"J. Clin. Invest."},{"key":"1245_CR55","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos, C. A. et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J. Clin. Oncol. 38, 3794\u20133804 (2020).","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1038\/s41587-025-02572-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000}},{"DOI":"10.1038\/s41587-026-03342-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000}}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01245-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01245-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01245-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:03:33Z","timestamp":1790661813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01245-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1038\/s41587-022-01245-x","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"24 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41587-025-02572-5","URL":"https:\/\/doi.org\/10.1038\/s41587-025-02572-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41587-026-03342-7","URL":"https:\/\/doi.org\/10.1038\/s41587-026-03342-7","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A., G.D. and Y.B. are inventors on patents related to the use of biomaterials for generation of CAR-T cell therapeutics. Y.B. receives an industry-sponsored research grant related to CAR-T cell therapeutic technology (unrelated to this work). G.D. is a paid consultant for Bellicum Pharmaceuticals, Tessa Therapeutics and Catamaran. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}